Rezlidhia (Olutasidenib)

Rezlidhia (olutasidenib) is an isocitrate dehydrogenase-1 (IDH1) inhibitor used for treating adults with isocitrate dehydrogenase-1 (IDH1)-mutated Acute Myeloid Leukemia (AML) when the cancer has returned or has not improved after previous therapeutic option(s).

Recommended Dosage: The recommended dosage is 150 mg taken by mouth twice daily until disease progression or unacceptable toxicity. Administer Rezlidhia capsules orally at around the same time each day. Avoid taking two doses within 8 hours. Take on an empty stomach either 60 minutes before or 120 minutes after a meal. Swallow capsules whole. It is not advisable to open, break, or chew the capsules. For those without disease progression or unacceptable toxicity, treatment for at least 6 months to allow time for clinical response.  

If any dose is vomited, avoid administering a replacement dose; wait until the very next scheduled dose is due. In case a dose is missed or not taken at around the standard time, administer the dose promptly and at least 8 hours before the next scheduled dose. Return to the standard schedule the following day. 

• Assess blood counts, and blood chemistries including liver function tests before starting therapy with Rezlidhia 150 mg, at least once weekly for the initial 2 months; once every other week for the 3rd month; once in the 4th month, and once every other month for the duration of therapy. Manage any potential abnormalities quickly.
  
• Rezlidhia 150 mg capsules can be responsible for causing hepatotoxicity, presenting as increased aspartate aminotransferase (AST), increased alanine aminotransferase (ALT), increased blood alkaline phosphatase, and/or elevated bilirubin. Monitor patients frequently for clinical signs or symptoms of hepatic dysfunction such as anorexia, fatigue, right upper abdominal discomfort, jaundice, or dark urine.
  
• Rezlidhia treatment can cause differentiation syndrome. If it is suspected, temporarily withhold treatment and start systemic corticosteroids (e.g., dexamethasone 10 mg IV every 12 hours) for at least 3 days and until resolution of probable signs and symptoms.
  
• Based on animal embryo-fetal toxicity studies, this medicine may be responsible for causing fetal harm if used on a pregnant woman. Because of the potential for side effects in a breastfed child, advise women not to breastfeed during treatment and for 14 days following the last dose.

What documents are required to import REZLIDHIA to India?

REZLIDHIA (olutasidenib) capsules can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patients ID proof (issued by the government of India)

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
  
• Import permit if applicable

REZLIDHIA (olutasidenib capsules) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Rezlidhia in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

IPN (Indian Pharma Network) can facilitate the supply of REZLIDHIA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Rezlidhia 150 mg price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the REZLIDHIA (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Rezlidhia®?

Olutasidenib is a Generic Name for the trade name drug Rezlidhia®.

What is the Manufacturer’s Name of Rezlidhia®?

Rezlidhia® is manufactured by Rigel and Forma Therapeutics, Inc.

Is Rezlidhia® approved by the FDA?

Yes, Rezlidhia® is approved by the FDA. Date of approval: December 1, 2022.

Where can I get Rezlidhia® at the best price in India?

To get the best Rezlidhia price in India, kindly connect with the Indian Pharma Network (a WHO GDP and ISO 9001:2008 certified company). For Rezlidhia®, a valid medical prescription is needed from a treating physician.

What is the dosage and form of Rezlidhia® supplied?

Rezlidhia® is supplied as Capsules: 150 mg for oral administration. 

What are the most common side effects of Rezlidhia®? 

The most common side effects of Rezlidhia® are rash, nausea, arthralgia, fatigue/malaise, constipation, dyspnea, mucositis, pyrexia, and diarrhea.

How much does Rezlidhia® cost in India?

The cost of Rezlidhia in India can vary. In order to procure this AML medication legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Rezlidhia®?

Store at a temperature of 20-25°C (68-77°F); excursions are permitted between 15-30°C (59°F and 86°F).

Is it safe to buy Rezlidhia® online in India?

Yes, one can buy Rezlidhia online in India at the lowest price from the Indian Pharma Network (IPN) if the medicine Rezlidhia® is not (yet) registered or available in their country. We can help facilitate the supply of Rezlidhia® through legal channels.